1. Chemically modified heparin or heparan sulfate with activity against factor IIa (anti-IIa activity) less than 10 IU / mg and activity against factor Xa (anti-Xa activity) less than 10 IU / mg and an average molecular weight (Mw) of about 4.6 to about 6.9 kDa, comprising: (i) polysaccharide chains substantially free of chemically intact saccharide sequences mediating an anticoagulant effect； and (ii) polysaccharide chains corresponding to molecular weights between 1.2 and 12 kDa, with a predominantly disaccharide formed according to (Formula I), where or n is an integer from 2 to 20, where the modified heparin or heparan sulfate contains unsaturated glucosamines at non-reducing ends, which presented as signals in the range from 5.0 to 6.5 ppm in the H-NMR spectrum with an intensity (%) of less than 4% relative to the natural heparin signal at 5.42 ppm, for use in combination with a treatment capable of activating maturation cervix or activate uterine myometrium contractions to induce labor in women. 2. Chemically modified heparin or heparan sulfate for use according to claim 1 in combination treatment with an agent for activating cervical maturation in women with an unripe cervix. 3. Chemically modified heparin or heparan sulfate for use according to claim 2, wherein the treatment for activating cervical ripening comprises administering prostaglandin. 4. A chemically modified heparin or heparan sulfate for use according to claim 3, wherein the prostaglandin is selected from the group consisting of dinoprostone (PGE2) and misoprostol. Chemically modified heparin or heparan sulfate for use according to claim 1, in combination treatment with an agent capable of activating myoma contractions1. Химически модифицированный гепарин или гепарансульфат с активностью против фактора IIa (анти-IIa-активностью) менее 10 МЕ/мг и активностью против фактора Ха (анти-Ха-активностью) менее 10 МЕ/мг и средней молекулярной массой (Mw) от около 4,6 до около 6,9 кДа, содержащий:(i) поли
